1/1/2018 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

Size: px
Start display at page:

Download "1/1/2018 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS"

Transcription

1 1/1/2018 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 1/1/18, Cigna is making changes to our formularies that may impact medication coverage for customers at your pharmacy. We have included a list of drugs by drug class that will be considered non-covered, non-preferred brand or require prior approval from Cigna for coverage, as well as the covered alternatives. We sent letters to affected customers explaining the coverage changes to their current medications. However, if a customer with Cigna pharmacy benefits does come in and attempts to refill a medication that is not covered, when appropriate, we ask that you assist him or her in the following ways: Mention the alternative covered drugs available in the chart on the next page Urge the customer to meet with the prescriber to discuss these alternatives or please call the prescriber to facilitate the new prescription Help the customer fill out the simple form on the last page to bring to his or her prescriber If you have questions, please see below: Question: Point of Service and Processing Phone Number: Issue Type: Refill too Soon Drug Coverage Issues Copay Issues You will need the following information for the phone prompts: Customer ID Customer DOB Prescription Information Pharmacy Contract Provider.Relations@optum.com Contract inquiries Reimbursement Optum.com/pharmacycareservices Select Pharmacists Reimbursement All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc Cigna.

2 Drug Coverage Changes by Class For Drugs Covered Under the Pharmacy Benefit Please note that this list only applies to our non-medicare Standard Prescription Drug List and does not reflect the entire list of covered and not-covered drugs for this or any other Cigna drug list. DRUG(S) NOT COVERED IN ^ DRUG(S) COVERED IN DRUG CLASS ANXIETY/DEPRESSION/BIPOLAR Anafranil clomipramine DISORDER Pamelor nortriptyline Parnate tranylcypromine Tofranil imipramine ASTHMA/COPD/RESPIRATORY Zyflo montelukast, zafirlukast, zileuton ER Zyflo CR zileuton ER ATTENTION DEFICIT Desoxyn methamphetamine HYPERACTIVITY DISORDER Dexedrine dextroamphetamine, dextroamphetamine ER BLOOD PRESSURE/HEART Betapace sotalol tablets MEDICATIONS CANCER Nilandron nilutamide DIABETES Invokamet, Invokamet XR Synjardy, Synjardy XR, Xigduo XR Invokana Farxiga, Jardiance Lantus, Lantus SoloStar, Toujeo Basaglar, Levemir, Tresiba SoloStar Novolin, Novolog Humalog, Humulin GASTROINTESTINAL/HEARTBURN Cortifoam, Uceris rectal foam Anucort-HC, Colocort, Hemmorex-HC, hydrocortisone, Procto-Med HC, Procto-Pak, Proctosol-HC, Proctozone-HC Lotronex alosetron Marinol dronabinol omeprazole bicarbonate packets, omeprazole mg capsules Rowasa mesalamine enema Uceris tablet budesonide EC capsule Zegerid omeprazole Zofran ondansetron Zofran ODT ondansetron ODT HORMONAL AGENTS DDAVP desmopressin Hectorol doxercalciferol capsule INFECTIONS Augmentin, Augmentin ES, Augmentin XR amoxicillin-clavulanate ER, amoxicillin clavulanate Diflucan fluconazole E.E.S. 200, Eryped 400 erythromycin ethylsuccinate Mepron atovaquone Sporanox itraconazole

3 INFECTIONS Targadox Avidoxy tablet, doxycycline hyclate, Morgidox capsule Valcyte valganciclovir Vancocin Zovirax vancomycin capsule acyclovir MISCELLANEOUS Gralise, Horizant gabapentin PAIN RELIEF AND INFLAMMATORY DISEASE Cambia D.H.E. 45, Migranal Imitrex, Sumavel DosePro Lorzone OxyContin Roxicodone Tivorbex Vanatol LQ Vivlodex Zomig Zorvolex PARKINSON'S DISEASE Lodosyn carbidopa Requip XL ropinirole ER SCHIZOPHRENIA/ANTI- Geodon ziprasidone PSYCHOTICS Zyprexa olanzapine diclofenac, diclofenac ER, etodolac, etodolac ER, fenoprofen, Fenortho, flurbiprofen, ibuprofen, indomethacin, indomethacin ER, ketoprofen, Ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone dihydroergotamine sumatriptan chlorzoxazone Embeda, Hysingla ER, Xtampza ER oxycodone indomethacin butalbital/acetaminophen/caffeine tabs or caps meloxicam sumatriptan, zolmitriptan diclofenac, diclofenac ER Zyprexa Zydis olanzapine ODT SKIN CONDITIONS Cutivate fluticasone cream Kenalog triamcinolone spray Locoid lotion hydrocortisone butyrate Luzu ketoconazole cream Soriatane acitretin Ziana clindamycin-tretinoin SLEEP DISORDERS/SEDATIVES Nuvigil armodafinil Provigil modafinil Restoril temazepam URINARY TRACT CONDITIONS Detrol tolterodine Detrol LA Ditropan XL Enablex Gelnique tolterodine ER oxybutynin ER darifenacin ER darifenacin ER, oxybutynin ER, tolterodine ER, trospium ER

4 ATTENTION DEFICIT HYPERACTIVITY DISORDER NON-PREFERRED BRAND DRUG(S) Adderall XR Focalin XR GENERIC AND/OR PREFERRED BRAND ALTERNATIVES dextroamphetamineamphetamine ER dexmethylphenidate ER SKIN CONDITIONS Ala-Scalp hydrocortisone Analpram HC lotion Capex shampoo Cordran Nucort, Texacort hydrocortisone-pramoxine fluocinolone flurandrenolide hydrocortisone DRUG(S) REQUIRING PRIOR ADDITIONAL INFORMATION AUTHORIZATION GASTROINTESTINAL/HEARTBURN HORMONAL AGENTS Akynzeo, Anzemet, Emend, Sancuso, Varubi Androderm, Androgel, Striant, testosterone Your plan will only cover this medication if the customer s doctor requests and receives approval from Cigna. DRUG(S) WITH QUANTITY ADDITIONAL INFORMATION LIMITS ALLERGY/NASAL SPRAYS cromolyn oral, mometasone Your plan only covers a certain ALZHEIMER'S DISEASE Namenda XR, Namzaric amount of this medication over a certain number of days. ANXIETY/DEPRESSION/BIPOLAR desvenlafaxine 25mg, 100mg, DISORDER Marplan, Pristiq ASTHMA/COPD/RESPIRATORY Perforomist BLOOD PRESSURE/HEART Ranexa MEDICATIONS CANCER Fareston, nilutamide EYE CONDITIONS bimatoprost eye drops, Cystaran, Zioptan HORMONAL AGENTS Alora, estradiol patch, Estring, Menostar, Minivelle, Vagifem, Vivelle-Dot, yuvafem MISCELLANEOUS Nuedexta OSTEOPOROSIS PRODUCTS alendronate PAIN RELIEF AND INFLAMMATORY Daliresp, Mitigare DISEASE SCHIZOPHRENIA/ANTI- Fanapt PSYCHOTICS SEIZURE DISORDERS Gabitril, Potiga SKIN CONDITIONS Denavir, Regranex, Santyl, Vectical SLEEP DISORDERS/SEDATIVES Hetlioz STEP THERAPY GENERIC AND/OR PREFERRED BRAND ALTERNATIVES ATTENTION DEFICIT Focalin XR dexmethylphenidate ER HYPERACTIVITY DISORDER SCHIZOPHRENIA/ANTI- Orap pimozide PSYCHOTICS SKIN CONDITIONS Ala-Scalp hydrocortisone Capex shampoo fluocinolone Cordran flurandrenolide Nucort, Texacort hydrocortisone

5 DOSE OPTIMIZATION - DRUG STRENGTH WITH LIMITATIONS^^ (Plan does not cover 2 capsules/ tablets per day) COVERED DRUG STRENGTH (Prescription must be for this strength) ALLERGY/NASAL SPRAYS desloratadine ODT 2.5mg desloratadine ODT 5mg ANXIETY/DEPRESSION/BIPOLAR DISORDER BLOOD PRESSURE/HEART MEDICATIONS Fetzima ER 20mg Fetzima ER 40mg Trintellix 5mg Trintellix 10mg Azor 5-20mg Benicar 20mg Benicar HCT mg Bystolic 10mg Tekturna 150mg Tekturna HCT mg Fetzima ER 40mg Fetzima ER 80mg Trintellix 10mg Trintellix 20mg Azor 10-40mg Benicar 40mg Benicar HCT 40-25mg Bystolic 20mg Tekturna 300mg CHOLESTEROL MEDICATIONS Livalo 1mg Livalo 2mg Livalo 2mg Tekturna HCT mg Livalo 4mg DIABETES Farxiga 5mg Farxiga 10mg PAIN RELIEF AND INFLAMMATORY Uloric 40mg Uloric 80mg DISEASE SCHIZOPHRENIA/ANTI- Latuda 60mg Latuda 120mg PSYCHOTICS SEIZURE DISORDERS Aptiom 200mg Aptiom 400mg Aptiom 400mg Fycompa 4mg Fycompa 6mg Trokendi XR 25mg Trokendi XR 100mg Aptiom 800mg Fycompa 8mg Fycompa 12mg Trokendi XR 50mg Trokendi XR 200mg SLEEP DISORDERS/SEDATIVES Silenor 3mg Silenor 6mg EAR MEDICATIONS GASTROINTESTINAL/HEARTBURN INFECTIONS NUTRITIONAL/DIETARY PAIN RELIEF AND INFLAMMATORY DISEASE SEIZURE DISORDERS BENEFIT PLAN EXCLUSIONS* Cortane-B Lotion Donnatal Elixir, Gelclair Oral Gel Packet, Proctocort 30 Mg Suppository Benzodox 30 Kit, Benzodox 60 Kit, Urelle Tablet Feriva FA Capsule Analpram HC 2.5%-1% Crm Single, Prodrin Caplet Smartrx Gabakit

6 SKIN CONDITIONS BENEFIT PLAN EXCLUSIONS* Ala-Quin 3-0.5% Cream, Avar 9.5%-5% Foam, Avar 9.5-5% Cleansing Pads, Avar LS 10%-2% Foam, Avar LS 10-2% Cleansing Pads, Avar LS Cleanser, Avar-E LS Cream, Dermasorb AF Complete Kit, Inova 4% Easy Pad, Inova 4-1 Easy Pad, Inova 8-2 Easy Pad, Iodoflex Pad, Keralac 47% Cream, Neosalus Foam, Ovace 10% Wash, Ovace Plus 10% Shampoo, Ovace Plus 10% Wash, Ovace Plus 9.8% Foam, Ovace Plus 9.8% Lotion, Ovace Plus Wash 10% Clnsng Gel, Plexion % Cleanser, Plexion % Clnsing Cloth, Plexion % Cream, Plexion % Lotion, Rynoderm 37.5% Topical Cream, Salex 6% Cream Kit, Salex 6% Lotion Kit, Salex 6% Shampoo, Salvax 6% Foam, Selrx 2.3% Shampoo, Sumadan 9%- 4.5% Wash, Sumadan Kit, Sumadan XLT Kit, Sumaxin Cleansing Pads, Sumaxin CP Kit, Sumaxin TS Topical Suspension, Sumaxin Wash, Ultrasal-ER 28.5% Solution, Uramaxin GT 45% Pre-Filled App, Urevaz 44% Cream, Vanoxide-HC Lotion, Virasal Antiviral Wart Remover, Vytone Cream Packet, Zithranol 1% Shampoo ^ These medications are not covered in our formularies; however, health care professionals can ask Cigna to consider approving coverage through a medical necessity review process. Through this process, health care professionals must show that covered alternatives failed to produce results for the patient and therefore a non-covered medication should be considered for coverage. ^^ These drugs are part of the Dose Optimization program. There is a medical necessity review process in place for customers who have proven a higher dose once per day is not clinically appropriate and require the use of a lower strength twice per day. * This product s eligibility for coverage varies by manufacturer because not all versions of the product have been approved by the FDA for marketing. Products not approved by the FDA for marketing are excluded from coverage under benefit plans.

7 Drug Coverage Changes by Class For Drugs Covered Under the Medical Benefit This list only applies to our non-medicare Standard Prescription Drug List and does not reflect the entire list of covered and not-covered drugs for this or any other Cigna drug list. Please note that drugs are listed alphabetically by brand name, with the generic name in parenthesis. GASTROINTESTINAL/HEARTBURN DRUG(S) REQUIRING PRIOR AUTHORIZATION Adriamycin (Doxorubicin Hcl), Adrucil (Fluorouracil), Alkeran (Melphalan Hcl), Aloxi (Palonosetron Hcl), Arranon (Nelarabine), Arzerra (Ofatumumab), Bleomycin (Bleomycin Sulfate), Camptosar (Irinotecan Hcl), Cerubidine (Daunorubicin Hcl), Clolar (Clofarabine), Cosmegen (Dactinomycin), Cytosar-U (Cytarabine), Dacogen (Decitabine), Depocyt (Cytarabine Liposome/Pf), Doxil (Doxorubicin Hcl Peg-Liposomal), Dtic-Dome (Dacarbazine), Ellence (Epirubicin Hcl), Eloxatin (Oxaliplatin), Emend (Fosaprepitant Dimeglumine), Faslodex (Fulvestrant), Fludara (Fludarabine Phosphate), Folotyn (Pralatrexate), Fudr (Floxuridine), Fusilev (Levoleucovorin Calcium), Gemzar (Gemcitabine Hcl), Hycamtin (Topotecan Hcl), Idamycin (Idarubicin Hcl), Ifex (Ifosfamide), Istodax (Romidepsin), Ixempra (Ixabepilone), Leustatin (Cladribine), Mustargen (Mechlorethamine Hcl), Mutamycin (Mitomycin), Navelbine (Vinorelbine Tartrate), Nipent (Pentostatin), Novantrone (Mitoxantrone Hcl), Oncaspar (Pegaspargase), Paraplatin (Carboplatin), Platinol (Cisplatin) Proleukin (Aldesleukin), Taxol (Paclitaxel), Taxotere (Docetaxel), Temodar (Temozolomide), Tepadina (Thiotepa), Toposar (Etoposide), Torisel (Temsirolimus), Trisenox (Arsenic Trioxide), Velban (Vinblastine Sulfate), Velcade (Bortezomib) Vidaza (Azacitidine), Vincasar (Vinblastine Sulfate), Vumon (Teniposide), Zanosar (Streptozocin) ADDITIONAL INFORMATION Your plan will only cover this medication if the customer s doctor requests and receives approval from Cigna.

8 Medication name: I am currently taking: Available alternatives: Strength: Directions: Medication name: I am currently taking: Available alternatives: Strength: Directions: Medication name: I am currently taking: Available alternatives: Strength: Directions:

CHANGES TO YOUR DRUG LIST

CHANGES TO YOUR DRUG LIST CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money As your health partner, we want to help you get and stay healthy. That means making sure you have access

More information

PRESCRIPTION DRUG LIST CHANGES

PRESCRIPTION DRUG LIST CHANGES PRESCRIPTION DRUG LIST CHANGES Cigna Pharmacy Management 2018 The medications listed below are changing coverage (or cost levels) on Cigna s Prescription Drug List. Changes are listed by drug list name

More information

PRESCRIPTION DRUG LIST CHANGES

PRESCRIPTION DRUG LIST CHANGES PRESCRIPTION DRUG LIST CHANGES For Providers 2018 Changes are being made to Cigna s Prescription Drug List that may affect some of your patients. These changes are listed by drug list name and by effective

More information

CHANGES TO YOUR DRUG LIST

CHANGES TO YOUR DRUG LIST CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money As your health partner, we want to help you get and stay healthy. That means making sure you have access

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

PRESCRIPTION DRUG LIST CHANGES

PRESCRIPTION DRUG LIST CHANGES PRESCRIPTION DRUG LIST CHANGES For Providers 2018 Changes are being made to Cigna s Prescription Drug List that may affect some of your patients. These changes are listed by drug list name and by effective

More information

PRESCRIPTION DRUG LIST CHANGES

PRESCRIPTION DRUG LIST CHANGES PRESCRIPTION DRUG LIST CHANGES Cigna Pharmacy Management 2018 The medications listed below are changing coverage (or cost levels) on Cigna s Prescription Drug List. Changes are listed by drug list name

More information

PRESCRIPTION DRUG LIST CHANGES

PRESCRIPTION DRUG LIST CHANGES PRESCRIPTION DRUG LIST CHANGES Cigna Pharmacy Management 2018 The medications listed below are changing coverage (or cost levels) on Cigna s Prescription Drug List. Changes are listed by drug list name

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A

More information

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:

More information

Alprazolam 0.25mg, 0.5mg, 1mg tablets

Alprazolam 0.25mg, 0.5mg, 1mg tablets Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service

More information

1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS 1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 1/1/19, Cigna is making changes to our formularies that may impact medication coverage for customers at your pharmacy. We have included a

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the

More information

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV 09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

ALLERGIC CONJUNCTIVITIS AGENTS

ALLERGIC CONJUNCTIVITIS AGENTS 2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops

More information

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna and Biologic Coverage Policy Subject Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 11 References... 11 Effective Date...2/15/2018

More information

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5

More information

2017 Step Therapy Criteria

2017 Step Therapy Criteria FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.

More information

Ovarian Cancer. compendia TREATMENT OF

Ovarian Cancer. compendia TREATMENT OF drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end

More information

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) 09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT

More information

Avoid paying too much for your prescriptions

Avoid paying too much for your prescriptions Quality health plans & benefits Healthier living Financial well-being Intelligent solutions 2017 Aetna Rx Step Program Medicine List Avoid paying too much for your prescriptions It s important to try to

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,

More information

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end

More information

Prescription benefit updates Large group

Prescription benefit updates Large group Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009 2018 2018 Simply Step Therapy Document September 2018 Aptiom APTIOM 200 MG TABLET APTIOM 400 MG TABLET Y0114_18_33074_I_009 APTIOM 600 MG TABLET APTIOM 800 MG TABLET Criteria If the patient has tried a

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018 Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Step Therapy Requirements

Step Therapy Requirements Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet

More information

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black

More information

Introduction to Antineoplastic Prescribing

Introduction to Antineoplastic Prescribing Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand

More information

Re: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification

Re: Integrated Oncology Management Program with evicore healthcare: Update on codes requiring precertification Ajani Nimmagadda, MD Senior Medical Director , , Re: Integrated Oncology Management Program with evicore

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018 Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Corporate Medical Policy

Corporate Medical Policy Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure

More information

Chemotherapy 101 for Radiation Oncology Workers

Chemotherapy 101 for Radiation Oncology Workers Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent

More information

ADHD STIMULANTS-S(SHC)

ADHD STIMULANTS-S(SHC) Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug

More information

Guideline Update on Antiemetics

Guideline Update on Antiemetics Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction

More information

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205

More information

UP Health System Marquette Medication Guideline High Alert Drugs

UP Health System Marquette Medication Guideline High Alert Drugs 1 ALTEPLASE SOLR 100 MG ACTIVASE 305010 50242008527 TRUE ALTEPLASE SOLR 50 MG ACTIVASE 305008 50242004413 TRUE AMIODARONE INJ 50 MG/ML CORDARONE IV 305035 63323061609 TRUE AMIODARONE INJ 50 MG/ML CORDARONE

More information

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed

More information

Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015

Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015 Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION

More information

SmithRx Standard Formulary Step Therapy List

SmithRx Standard Formulary Step Therapy List SmithRx Standard Formulary Step Therapy List Revised: January 27, 2017 The following medications require prior use of at least one other medication for coverage. Please note that any plan-specific customizations

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration

Melanoma. compendia. Associated ICD-9-CM Codes: Drug & Administration Drug & Administration compendia Treatment of Melanoma With each publication, ManagedCare Oncology s Drug & Administration Compendia highlights a single medication or a group of medications that could be

More information

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet ) Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important

More information

Prescription benefit updates Large group

Prescription benefit updates Large group Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

Prior Authorization Proposal: Oncology Agents

Prior Authorization Proposal: Oncology Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

FirstCarolinaCare Insurance Company. Step Therapy Requirements

FirstCarolinaCare Insurance Company. Step Therapy Requirements FirstCarolinaCare Insurance Company Step Therapy Requirements Effective: 12/01/2018 ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date: Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

U T I L I Z A T I O N E D I T S

U T I L I Z A T I O N E D I T S I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental

More information

Managements of Chemotherpay Induded Nausea and Vomiting

Managements of Chemotherpay Induded Nausea and Vomiting REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA

More information

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion

More information

UNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization

UNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization UNDERWRITING GUIDE Secure Advantage HOSPITAL COVERAGE The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization TABLE OF CONTENTS Contents Page Secure Advantage Underwriting Guide...2

More information

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET

More information

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK

More information

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 11/01/2018 Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK

More information

Lower your costs. Save money with preferred generic and preferred brand-name drugs 2018 Aetna Rx Step Program Medicine List

Lower your costs. Save money with preferred generic and preferred brand-name drugs 2018 Aetna Rx Step Program Medicine List Call out bold Call out light Contact information, call X-XXX-XXX-XXXX or visit www.aetna.com Call to action small copy (especially related to mobile apps). Hendani adionse rferum faceatis incte voluptassi

More information

AN ACTIVE, DISCIPLINED APPROACH TO FORMULARY MANAGEMENT TO DRIVE BETTER PLAN AFFORDABILITY

AN ACTIVE, DISCIPLINED APPROACH TO FORMULARY MANAGEMENT TO DRIVE BETTER PLAN AFFORDABILITY Cigna Pharmacy Management AN ACTIVE, DISCIPLINED APPROACH TO FORMULARY MANAGEMENT TO DRIVE BETTER PLAN AFFORDABILITY Changes begin 1/1/17 As part of the effort to position our pharmacy plans for long-term

More information

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date: Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy

More information

Drug Formulary Update, January 2018 Commercial and State Programs

Drug Formulary Update, January 2018 Commercial and State Programs Drug Formulary Update, January 2018 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

Drug Formulary Update, April 2017 Commercial and State Programs

Drug Formulary Update, April 2017 Commercial and State Programs Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information